The question of whether young age is an independent prognostic factor in breast cancer has divided researchers for decades. Breast cancer remains the fourth leading cause of cancer-related death worldwide, and young age at diagnosis has repeatedly been linked to higher recurrence rates and shorter disease-free survival. Skeptics have argued that the apparent disadvantage simply reflects confounding: young patients tend to present with more aggressive tumor biology, including high-grade disease, lymphovascular invasion, elevated proliferation, and an enrichment of hormone receptor-negative, HER2-positive, and basal-like tumors. They are also more frequently diagnosed at advanced stages. Yet several large analyses have found that young age persists as a risk factor even after adjustment for stage and receptor status, and patients under 35 show increased risks of recurrence and distant metastasis that pathological features alone cannot explain.

To dissect this puzzle, the study drew on the TCGA PanCancer Atlas Breast Invasive Carcinoma cohort accessed through cBioPortal. After a careful filtering process that excluded stage IV disease, unknown stages, and tumors with Normal-like or missing PAM50 classifications, the final analytical cohort comprised 821 patients with invasive ductal or invasive lobular carcinoma: 142 aged 45 years or younger and 679 older than 45. The cutoff of 45 years was chosen to align with previous genomic studies, and sensitivity analyses using thresholds of 35, 40, and 50 years were performed to guard against the arbitrariness of any single definition of “young.”

The clinicopathological comparison revealed that young patients were significantly more likely to have invasive ductal carcinoma, at 94.4 percent versus 79.4 percent in older patients, and more likely to have lymph node involvement, with only 38 percent showing node-negative disease compared with 51.2 percent of older patients. Notably, however, estrogen receptor, progesterone receptor, HER2 status, intrinsic subtype, tumor size, and overall stage distribution did not differ significantly between the groups. Survival analyses then showed that young patients had significantly worse disease-free survival, with a log-rank p-value of 0.001, while overall survival and disease-specific survival did not differ significantly. The absolute burden of recurrence was striking: five-year disease-free survival event rates were 23.1 percent in young patients versus 10.8 percent in older patients, widening to 35.7 percent versus 13.8 percent at ten years. Restricted mean survival time analysis quantified a loss of 2.9 months within five years and 13.9 months within ten years for young patients, indicating that the prognostic gap widened over time.

The core of the study lay in constructing the molecular signature. Differential expression analysis between age groups identified 614 age-associated genes at a false discovery rate below 0.1, while univariable Cox regression flagged 529 genes linked to disease-free survival at a p-value below 0.01. Intersecting these sets yielded 11 candidates, which were then subjected to LASSO-Cox regression with 10-fold cross-validation, followed by stepwise multivariable selection based on the Akaike information criterion. The result was a parsimonious four-gene model comprising C4orf14, also known as NOA1, LINC01124, ZNF704, and AGFG2. Each patient’s Sig4 score was calculated as a weighted linear combination of the log2-transformed expression values of these genes, with fixed regression coefficients derived from the TCGA cohort.

The statistical performance of Sig4 was the study’s most provocative finding. In univariable analysis, young age carried a hazard ratio of 2.44 for poor disease-free survival, and this association remained significant after adjustment for stage and intrinsic subtype. But when the continuous Sig4 score was added to the fully adjusted model, Sig4 itself emerged as a strong independent predictor, with a hazard ratio of 2.18 per one-standard-deviation increase, while the coefficient for young age attenuated to a statistically non-significant 1.43. The author is careful to note that this attenuation indicates overlapping prognostic information between age and the signature, but does not prove that Sig4 mediates or causally explains the age effect. Within the young subgroup alone, Sig4 remained independently associated with disease-free survival, a result reinforced by bootstrap resampling with 1000 iterations, and descriptive Kaplan-Meier curves showed significantly poorer survival among young patients with high Sig4 scores.

Biological context came from gene set enrichment analysis. Tumors with high Sig4 scores were enriched for proliferation- and cell cycle-related pathways, including MYC targets, E2F targets, the G2-M checkpoint, and mitotic spindle assembly, along with DNA repair, mTORC1 signaling, glycolysis, oxidative phosphorylation, and the unfolded protein response. In contrast, Sig4-low tumors showed relative enrichment of early and late estrogen response pathways. Single-sample enrichment analysis confirmed these differences at the individual tumor level. The four component genes themselves span diverse functions: NOA1 is a mitochondrial GTPase involved in mitoribosome biogenesis and respiration; LINC01124 is a long noncoding RNA implicated in proliferation and invasion; ZNF704 is a zinc finger repressor linked to circadian disruption and metastasis in breast cancer; and AGFG2 participates in vesicular trafficking, potentially reflecting tumor-microenvironment interactions.

External validation in the independent METABRIC cohort of 1134 matched cases provided partial support. Using the fixed TCGA-derived coefficients, the Sig4 score was significantly associated with worse relapse-free survival both as a continuous variable and when dichotomized at the cohort median, and Sig4-high status remained significant in multivariable models, in stratified Cox analyses, and in models incorporating a time-varying coefficient for young age. However, the validation was not uniformly successful: when the analysis was restricted to young METABRIC patients aged 45 or younger, the Sig4 score showed no significant association with relapse-free survival. The author attributes this to possible differences in cohort composition, treatment background, expression platform, endpoint definitions, and statistical precision, and concludes that the signature’s utility specifically for young-onset disease remains unproven.

The study is candid about its limitations. It is a retrospective analysis of public datasets with incomplete treatment and hereditary predisposition information, meaning that chemotherapy, endocrine therapy, HER2-targeted treatment, and germline BRCA status could all have influenced the observed associations. The limited number of disease-free survival events relative to the number of genes screened raises the specter of overfitting, despite the penalized regression approach, and the bulk RNA sequencing data cannot separate tumor-intrinsic programs from microenvironmental contributions. The author therefore positions Sig4 as an exploratory candidate signature rather than a clinically applicable biomarker, emphasizing that translation into practice would require analytical standardization, prospective validation, and evidence that the score improves decisions beyond existing clinicopathological and molecular tools. Even so, the work offers a compelling demonstration that the transcriptomic landscape of young-onset breast cancer carries prognostic weight, and it points toward a future in which age-associated molecular signatures could help identify which young patients truly need intensified surveillance and therapy.

Subject of Research: An age-associated four-gene prognostic signature for recurrence risk in breast cancer

Article Title: Age‐Associated Four‐Gene Prognostic Signature in Breast Cancer

Article References: Uchida, S. (2026). Age‐Associated Four‐Gene Prognostic Signature in Breast Cancer. Cancer Reports, 9(9), Article e70670. https://doi.org/10.1002/cnr2.70670

Image Credits: AI Generated

DOI: 10.1002/cnr2.70670

Keywords: breast cancer, prognostic signature, young-onset breast cancer, gene expression, TCGA, METABRIC, disease-free survival, LASSO-Cox regression, molecular biomarker, recurrence risk, transcriptomics, Cancer Reports

Researchers at Tampere University Hospital set out to answer a question that had not been addressed before: whether temporal muscle thickness, or TMT, measured on ordinary computed tomography scans, could predict survival in patients aged 70 or older who received brain radiotherapy for metastatic cancer. The question matters because prognostication in this population is exceptionally difficult and exceptionally important. Brain metastases affect an estimated 10 to 40 percent of patients with solid tumors, and population studies place the incidence between 8.3 and 14.3 per 100,000 people, a figure that almost certainly underestimates the true burden because not all cases are registered. Median survival across the field ranges from as little as two months to 21 months depending on the primary cancer, and for patients over 65, Surveillance, Epidemiology, and End Results data indicate a median survival of four months or less for nearly all common malignancies, including breast, colorectal, esophageal, renal, and lung cancer and melanoma.

Accurate prognostic tools would allow clinicians to tailor treatment intensity intelligently. Patients with a favorable outlook might benefit from more aggressive interventions, while those expected to survive only weeks could be spared the burdens of hospitalization, repeated radiotherapy sessions, or chemotherapy in the final weeks of life, interventions that may degrade quality of life without meaningfully extending it. Honest prognostic information also underpins shared decision-making, giving patients and families a realistic basis on which to weigh intensive treatment against palliative care. The Tampere team reasoned that if a simple measurement already embedded in the treatment-planning scan could sharpen these predictions, it would be a genuinely useful clinical instrument.

The study, published in Cancer Reports, took the form of a retrospective cohort analysis of consecutive patients aged 70 years or older who underwent brain radiotherapy, with or without prior surgical resection, for brain metastases between 2014 and 2022. From the hospital’s electronic radiotherapy database, 249 patients met the inclusion criteria: 136 men with a mean age of 76.0 years and 113 women with a mean age of 76.4 years. Lung cancer dominated the cohort, accounting for 113 patients or 45.4 percent, followed by breast cancer with 29 patients and melanoma with 27. Most participants, 226 in total, received radiotherapy alone, split between whole-brain radiotherapy, given to 151 patients, and stereotactic radiotherapy, delivered to 98, while 23 patients underwent surgical resection followed by postoperative radiation.

Measuring the temporalis muscle requires surprising methodological care. A single observer, blinded to patient outcomes, assessed TMT on each patient’s first radiotherapy planning head CT, or on a diagnostic CT performed within the preceding month. The measurement plane had to be oriented parallel to the falx cerebri, the membrane dividing the brain’s hemispheres, and tangential to the floor of the middle cranial fossa, with the image windowed to a narrow setting of 80 Hounsfield units width and 40 length to sharpen the muscle’s boundaries. On the first axial slice above the bony orbit, a tangent line was drawn from the muscle’s anterior attachment to the skull, and thickness was recorded at the muscle’s thickest point perpendicular to that line, deliberately excluding fat, fascia, and blood vessels. The average of left and right measurements was used in the analyses. To confirm the technique’s reliability, a second observer independently measured a random sub-cohort of 19 patients, and the agreement between readers was excellent, with an intraclass correlation coefficient of 0.942 for single measurements and 0.970 for averages—figures indicating that the measurement itself is robust and reproducible.

Because men naturally have thicker temporal muscles than women, the researchers derived sex-specific thresholds for low TMT by maximizing Youden’s index, a statistical measure balancing sensitivity and specificity, for three-month survival. The resulting cut-offs were 4.3 millimeters for men, with 46.7 percent sensitivity and 74.6 percent specificity, and 3.975 millimeters for women, with 64.6 percent sensitivity and 49.2 percent specificity. These thresholds are notably lower than those reported in earlier studies of younger patients, a difference the authors attribute to the advanced age of their cohort, in which temporal muscle wasting is already widespread. By these criteria, 35.3 percent of the men and 56.6 percent of the women had low temporal muscle thickness.

The survival picture in the cohort was stark. Median overall survival was just 90 days, or roughly three months, and by the one-year mark 86.7 percent of the patients had died. Patients with normal TMT did live somewhat longer on average than those with low TMT, with a median of 103 days versus 75 days, and in univariate analyses low TMT was significantly associated with worse survival at three months, with a hazard ratio of 1.54, and at six months, with a hazard ratio of 1.41. At one month and twelve months, no association reached statistical significance. But the crucial test came when the researchers adjusted their models for other clinical variables: age, body mass index, surgical treatment, and type of radiotherapy. Once these factors were accounted for, the relationship between TMT and survival evaporated entirely at every time horizon, with the adjusted three-month hazard ratio falling to 1.40 and losing significance.

What did predict survival, independently, were other clinical variables. Receiving whole-brain radiotherapy rather than stereotactic radiotherapy carried a substantially higher risk of death at every time point, with an adjusted hazard ratio of 5.98 for one-month survival and approximately 2.3 at the longer horizons. This likely reflects treatment selection rather than harm: whole-brain radiotherapy is generally reserved for patients with multiple metastases and poorer prognosis, while stereotactic techniques are favored for those with limited, more favorable disease. Similarly, patients who did not undergo surgical resection had markedly higher mortality across all time frames, since surgery is typically offered only to younger patients with solitary lesions and better expected outcomes. Higher body mass index was protective for one-month survival, with a hazard ratio of 0.31, and advancing age independently worsened six- and twelve-month survival. The authors are candid that these patterns largely mirror the realities of clinical decision-making.

The contrast with previous research is instructive. Of six earlier studies evaluating TMT in patients with brain metastases, three found that low thickness predicted shorter survival, while others found no association once confounders were considered. Crucially, those studies examined patients on average more than a decade younger, with median survival extending from three to eleven months, and several included only surgically treated patients. The Tampere cohort, by contrast, was older, sicker, and predominantly managed with radiotherapy alone. The researchers also tested whether TMT predicted survival within their largest tumor subgroup, the 113 lung cancer patients, and found no significant association at any time point, which discouraged further subgroup analyses. Additional limitations deserve mention: performance status, number of brain lesions, intracranial tumor volume, extracranial disease status, and systemic therapy were not incorporated into the models, and the derived sex-specific cut-offs may risk overfitting, making external replication essential.

The study’s conclusion is refreshingly direct: temporal muscle thickness should not be regarded as a prognostic factor in patients aged 70 or older with brain metastases treated with radiotherapy. The finding is a valuable corrective to a growing enthusiasm for imaging-derived body-composition markers, reminding clinicians and researchers that a measurement can be technically reliable, easily obtained, and biologically plausible yet still fail to add independent predictive value in the population that matters. In very old, profoundly ill patients whose median survival is measured in weeks, disease aggressiveness and treatment selection appear to overwhelm any signal carried by skeletal muscle reserves. For this vulnerable group, prognostic conversations must continue to rest on established clinical variables, while the search for better tools goes on.

Subject of Research: Temporal muscle thickness as a prognostic marker for survival in older patients with brain metastases treated with radiotherapy

Article Title: Association Between Temporal Muscle Thickness and Survival in Older Patients With Brain Metastases Undergoing Radiation Therapy

Article References: Pikkarainen, L., Korhonen, T. K., Tolonen, A., Pesonen, E. K., Hernandez, N., Skyttä, T., & Arponen, O. (2026). Association Between Temporal Muscle Thickness and Survival in Older Patients With Brain Metastases Undergoing Radiation Therapy. Cancer Reports, 9(9), Article e70671. https://doi.org/10.1002/cnr2.70671

Image Credits: AI Generated

DOI: 10.1002/cnr2.70671

Keywords: temporal muscle thickness, brain metastases, radiotherapy, survival, sarcopenia, cachexia, prognostication, computed tomography, whole-brain radiotherapy, stereotactic radiotherapy, older patients, Cancer Reports